These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 31715054)

  • 21. Paradoxical Arthritis Due to Ixekizumab in a Patient With Plaque Psoriasis.
    Vidal D; Ros S; Reina D
    Actas Dermosifiliogr (Engl Ed); 2019 Apr; 110(3):255-256. PubMed ID: 29861037
    [No Abstract]   [Full Text] [Related]  

  • 22. Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study.
    Deza G; Notario J; Lopez-Ferrer A; Vilarrasa E; Ferran M; Del Alcazar E; Carrascosa JM; Corral M; Salleras M; Ribera M; Puig L; Pujol RM; Vidal D; Gallardo F
    J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):553-559. PubMed ID: 30317679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrated safety analysis: Frequency of urinary tract infections in patients with psoriasis treated with ixekizumab.
    Smith SD; Conrad C; Ramharter M; Gottlieb AB; Patel H; Xu W; Riedl E; Schuster C
    J Am Acad Dermatol; 2020 Jul; 83(1):261-263. PubMed ID: 32092375
    [No Abstract]   [Full Text] [Related]  

  • 24. Efficacy and Safety of Ixekizumab in a Real-Life Practice: A Retrospective Bicentric Study.
    Magdaleno-Tapial J; Carmena-Ramón R; Valenzuela-Oñate C; Ortiz-Salvador JM; Sabater-Abad J; Hernández-Bel P; Gimeno-Carpio E; Sánchez-Carazo JL; Pérez-Ferriols A
    Actas Dermosifiliogr (Engl Ed); 2019 Sep; 110(7):585-589. PubMed ID: 31006480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis.
    Romiti R; Valenzuela F; Chouela EN; Xu W; Pangallo B; Moriarty SR; Gürbüz S; Riedl E
    Br J Dermatol; 2019 Jul; 181(1):202-203. PubMed ID: 30609008
    [No Abstract]   [Full Text] [Related]  

  • 26. Novel Therapeutic Approaches and Targets for Treatment of Psoriasis.
    Radi G; Campanati A; Diotallevi F; Bianchelli T; Offidani A
    Curr Pharm Biotechnol; 2021; 22(1):7-31. PubMed ID: 32598253
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Brodalumab success in patients with moderate-to-severe psoriasis who failed previous interleukin-17A inhibitors.
    Yeung J; Vender R; Turchin I; Shukla R; Maari C; Hong CH; Barakat M; Lansang P
    J Am Acad Dermatol; 2021 Apr; 84(4):1169-1171. PubMed ID: 33221464
    [No Abstract]   [Full Text] [Related]  

  • 28. No reactivation of tuberculosis in patients with latent tuberculosis infection receiving ixekizumab: A report from 16 clinical studies of patients with psoriasis or psoriatic arthritis.
    Mrowietz U; Riedl E; Winkler S; Xu W; Patel H; Agada N; Lebwohl MG
    J Am Acad Dermatol; 2020 Nov; 83(5):1436-1439. PubMed ID: 32526319
    [No Abstract]   [Full Text] [Related]  

  • 29. No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis.
    Bokor-Billmann T; Schäkel K
    J Dermatolog Treat; 2019 May; 30(3):216-220. PubMed ID: 30051725
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response to ixekizumab in a patient of psoriasis with secondary failure to secukinumab.
    Mittal S
    Indian J Dermatol Venereol Leprol; 2021; 87(1):119-121. PubMed ID: 33037161
    [No Abstract]   [Full Text] [Related]  

  • 31. Eczematous eruption during anti-interleukin 17 treatment of psoriasis: an emerging condition.
    Napolitano M; Megna M; Fabbrocini G; Nisticò SP; Balato N; Dastoli S; Patruno C
    Br J Dermatol; 2019 Sep; 181(3):604-606. PubMed ID: 30768788
    [No Abstract]   [Full Text] [Related]  

  • 32. Long-term control of spondylitis by short-term ixekizumab treatment in a patient with palmoplantar pustulosis.
    Ikumi N; Fujita H
    J Dermatol; 2024 Aug; 51(8):e255-e256. PubMed ID: 38414168
    [No Abstract]   [Full Text] [Related]  

  • 33. Real-world efficacy and safety of interleukin-17 inhibitors for psoriasis: A single-center experience.
    Ohata C; Ohyama B; Katayama E; Nakama T
    J Dermatol; 2020 Apr; 47(4):405-408. PubMed ID: 31994229
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis: Subgroup analysis of Latin American patients in the phase 3 randomized UNCOVER-3 study.
    Valenzuela F; de la Cruz Fernandez C; Galimberti RL; Gürbüz S; McKean-Matthews M; Goncalves L; Romiti R
    Actas Dermosifiliogr; 2017; 108(6):550-563. PubMed ID: 28342534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed.
    Kimmel G; Chima M; Kim HJ; Bares J; Yao CJ; Singer G; Kim SJ; Bagel J; Lebwohl M
    J Am Acad Dermatol; 2019 Sep; 81(3):857-859. PubMed ID: 31078609
    [No Abstract]   [Full Text] [Related]  

  • 36. Paradoxical reversed plantar involvement during ixekizumab therapy for psoriasis.
    Martínez-Doménech Á; García-Legaz-Martínez M; Magdaleno-Tapial J; Giácaman M; Hernández-Bel P; Pérez-Ferriols A
    Dermatol Online J; 2019 Apr; 25(4):. PubMed ID: 31046917
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The safety of ixekizumab in psoriasis drug therapy.
    Puig L
    Expert Opin Drug Saf; 2020 Feb; 19(2):117-130. PubMed ID: 31874129
    [No Abstract]   [Full Text] [Related]  

  • 38. Long-term efficacy and safety results from an open-label phase III study (UNCOVER-J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab.
    Umezawa Y; Torisu-Itakura H; Morisaki Y; ElMaraghy H; Nakajo K; Akashi N; Saeki H;
    J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):568-576. PubMed ID: 30325534
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of ixekizumab in patients with resistance or incomplete response to secukinumab.
    Hegazy S; Konstantinou MP; Bulai Livideanu C; Tauber M; Paul C
    J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):e338-e341. PubMed ID: 31001858
    [No Abstract]   [Full Text] [Related]  

  • 40. The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis.
    Reich K; Puig L; Mallbris L; Zhang L; Osuntokun O; Leonardi C
    J Eur Acad Dermatol Venereol; 2017 Jul; 31(7):1196-1207. PubMed ID: 28370467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.